Eliquis
Anticoagulant medicine
1 conceptEliquis is the apixaban anticoagulant franchise jointly marketed by Bristol Myers Squibb and Pfizer.
ProductsBristol Myers Squibb
Bristol Myers Squibb product analyses
A tighter look at the products that matter most to Bristol Myers Squibb, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Opdivo
Immuno-oncology medicine
1 conceptOpdivo is BMS's nivolumab immuno-oncology franchise, used across multiple cancer indications and combinations.
Paper trail
Company-level source stack
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Bristol Myers Squibb 2025 Annual Report
Bristol Myers Squibb · annual report
Primary company filing source for business description, risk factors, revenues, product portfolio, and profitability context.
Reviewed 2026-05-27
Bristol Myers Squibb Key Facts
Bristol Myers Squibb · investor relations
Company-maintained fact page summarizing 2025 product revenue, including Eliquis and Opdivo.
Reviewed 2026-05-27
Bristol-Myers Squibb Company Market Cap and Stock Overview
StockAnalysis · market data
Market-data source for May 2026 market capitalization and P/E ratio cross-check.
Reviewed 2026-05-27